ADMA Biologics (NASDAQ:ADMA) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a strong sell rating to a hold rating in a report published on Monday,Zacks.com reports.

A number of other brokerages also recently commented on ADMA. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group decreased their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Raymond James Financial began coverage on ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Mizuho cut their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $9.21 on Monday. The stock’s 50-day moving average is $8.62 and its 200-day moving average is $12.82. The company has a market cap of $2.13 billion, a price-to-earnings ratio of 13.54 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.11 EPS. Equities analysts anticipate that ADMA Biologics will post 0.82 earnings per share for the current year.

Insider Activity

In other news, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This represents a 2.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently bought and sold shares of ADMA. Royal Bank of Canada grew its position in shares of ADMA Biologics by 112.7% during the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of ADMA Biologics during the first quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after purchasing an additional 305,064 shares in the last quarter. Norges Bank bought a new stake in ADMA Biologics in the second quarter valued at about $549,000. Finally, EverSource Wealth Advisors LLC increased its holdings in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: One market note from Zacks highlighted that ADMA Biologics had recently outperformed the broader market, reflecting some underlying trading resilience despite the legal headlines. Article Title
• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Pomerantz, Robbins Geller, KSF, and others, issued reminders about the August 10, 2026 lead-plaintiff deadline in the already-filed securities class action. These notices do not change the case itself, but they keep the issue in the spotlight. Article Title
• Neutral Sentiment: The litigation centers on allegations that ADMA Biologics misled investors about revenue growth and internal controls during the August 9, 2024 to March 25, 2026 period. The claims are still allegations, but they add uncertainty around the company’s prior reporting. Article Title
• Negative Sentiment: The biggest headwind is the short-seller-related fraud narrative: several notices reference claims that ADMA’s reported ASCENIV revenue growth may have been overstated through channel stuffing, which reportedly helped trigger a sharp stock selloff. That allegation is the main reason shares are under pressure. Article Title

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.